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Protein Phosphorylation as a Key Mechanism for the Regulation 
of BCL-3 Activity
ABSTRACT
Constitutive NF-κB activation, a hallmark of many human cancers, upregulates
anti-apoptotic gene expression and therefore disrupts the balance between apoptosis and
proliferation. In some lymphomas, this constitutive NF-κB activity is the result of point
mutations or translocations of the genes coding for NF-κB inhibitors, namely IκBα or
p100. The BCL-3 protein is another member of the IκB family and is overexpressed in a
subset of human B-cell chronic lymphocytic leukemias because of a chromosomal translo-
cation. This oncoprotein is phosphorylated by multiple kinases including GSK3 and this
phosphorylation regulates BCL-3 function by modulating its oncogenic potential and by
regulating the expression of a subset of its target genes. Therefore, deciphering the
NF-κB/IκB protein phosphorylations is critical in order to better understand the molecular
mechanisms of NF-κB-mediated oncogenesis.
INTRODUCTION
NF-κB is a critical family of proteins that play crucial roles in inflammation, immunity,
cell proliferation and apoptosis. NF-κB exists in a latent stage in the cytoplasm bound to
inhibitory proteins collectively called IκBs.1 A variety of extracellular stimuli, including
cytokines, pathogens or pathogens-related factors trigger signalling pathways that ultimately
lead to the phosphorylation and subsequent proteasome-mediated degradation of the
IκB.1 Activated NF-κB subsequently migrate into the nucleus to regulate the expression
of multiple target genes. As an ankyrin repeats-containing protein, BCL-3 is a member of
the IκB family but its function is not similar to the other IκBs.
BCL-3 was originally identified by molecular cloning of the breakpoint of the t(14 ;19)
chromosomal translocation from a subset of human B-cell chronic lymphocytic
leukemias.2 This translocation causes BCL-3 overexpression and presumably dysregulation
of still mostly unknown downstream target genes involved in cell proliferation, apoptosis
and differentiation.3 Enhanced BCL-3 expression due to gene amplification is also a
marker to differentiate t(2,5)-positive anaplastic large cell lymphoma from Hodgkin
disease.4 Moreover, high BCL-3 expression has also been described in solid tumors such
as nasopharyngeal carcinomas5 and breast cancers.6
BCL-3 IS A TRANSCRIPTION FACTOR
Unlike the other members of the IκB family, BCL-3 is a nuclear protein and has been
described as a transcriptional activator or repressor through formation of heterocomplexes
with the NF-κB proteins p50 and p52.7-10 Although the molecular mechanisms underlying
BCL-3-mediated transcription is unclear, BCL-3 harbors two transactivating domains
located upstream and downstream the ankyrin repeats. BCL-3 activates transcription by
removing inhibitory p50 homodimers from κB sites9 while in other circumstances, it
represses gene expression.11 BCL-3 physically interacts with coactivators such as JAB1,
Bard1 and Tip6012 but also with transcriptional repressors such as HDAC1, -3 and -613,14
which could explain its dual role as a transcription activator or repressor. Although a clear
demonstration of the physiological role of these interactions is still missing, a recent report
demonstrated that the ability of BCL-3 to recruit HDAC1 is required to inhibit LPS-
induced inflammatory responses in macrophages.13 Another study even describes BCL-3
as a coactivator itself that is required for the expression of a subset of NF-κB target genes
such as IP-10 in response to TNFα.15 How could all these interactions with NF-κB
proteins, coactivators and repressors be interpreted to better understand BCL-3 regulation
of gene transcription? A study demonstrated that IL-1β stimulation
triggers nuclear export of a specific corepressor complex and recruit-
ment of a Tip60-containing activator complex by BCL-3 which is
constitutively present within the promoter. As a result, a specific
subset of NF-κB target genes are expressed upon cell stimulation.16
However, this experimental model does not explain why BCL-3 acti-
vates but also represses gene transcription. This issue remains unclear
to date but the answer may come from post-translational modifica-
tion of BCL-3 itself. In any case, our preliminary results indeed indi-
cate that, when overexpressed in NIH3T3 cells, BCL-3 induced the
expression of about one hundred genes whereas twenty other candi-
dates were repressed (unpublished results). Therefore, the dual role
of BCL-3 regarding transcriptional activation or repression appears
to be relevant.
BCL-3 ONCOGENICITY IS REGULATED BY PHOSPHORYLATION
Similarly to the NF-κB proteins, it is well accepted, although not
yet proven, that the oncoprotein BCL-3 exerts its effect through
direct regulation of gene expression. In this context, BCL-3 onco-
genic potential has been recently demonstrated in vitro and in
vivo.14 Indeed, BCL-3 expressing NIH3T3 cells are transformed
and form tumors when injected in nude mice. Moreover, the BCL-3
target genes that mediate this oncogenic potential have been identi-
fied14 and include target genes such as SLPI which is known to pro-
mote the tumorigenic and metastatic potential of cancer cells.17
Interestingly, BCL-3 oncogenicity is attenuated by GSK3-dependent
phosphorylation on its C-terminal domain and this phosphorylation
triggers BCL-3 degradation through the proteasome pathway.
Therefore, this mechanism physiologically limits intracellular
BCL-3 levels and prevents BCL-3 oncogenicity. Although the
consequences of BCL-3 phosphorylation on gene transcription
remain largely unexplored, we demonstrated that GSK3-mediated
BCL-3 phosphorylation modulates its interactions with the HDAC
proteins and regulates BCL-3 ability to induce a subset of its target
genes.14 However, the expression of many BCL-3 target genes is not
regulated by GSK3-mediated BCL-3 phosphorylation, which does
not rule out the possibility that BCL-3 phosphorylation by other
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Figure 1. BCL-3 phosphorylation modulates its transcription potential. The kinase GSK3 phosphorylates BCL-3 on two residues within its C-terminal domain
and this phosphorylation triggers ubiquitin linkage and proteasome-mediated BCL-3 degradation. In macrophages, LPS stimulation through the TLR4 triggers
IRAK phosphorylation by the kinase IRAK4 and susbsequent recruitment of TRAF6 to the cell membrane. An LPS-inducible kinase subsequently phosphory-
lates nuclear BCL-3 but this activated kinase remains to be identified. In the nucleus, BCL-3 recruits either some coactivators such as Tip60 or HDAC
proteins in order to activate or repress transcription, respectively.
kinases may modulate BCL-3 transcriptional potential. Indeed, it
has been known for many years that BCL-3 is heavily phosphorylated
in several cell types including lymphoma cell lines.8,14,18,19 Nuclear
BCL-3 is phosphorylated upon LPS treatment13 and we have recently
identified a BCL-3 kinase distinct from GSK3 that is known to be
activated by LPS (unpublished results). Therefore, at least two kinases
phosphorylate BCL-3 in vivo. The biological consequences of this
second phosphorylation on BCL-3 mediated gene transcription and
on cellular transformation remains unknown but these issues are
currently being addressed in our laboratory. It also remains to be
determined whether BCL-3 is simultaneously phosphorylated by
multiple kinases in any cell type or whether some cell specificity
occurs.
Genetic disruption of the bcl-3 gene in mice indicated that
BCL-3 is required for antigen-specific priming of T and B cells since
mutant mice are impaired in germinal center reactions and T-depen-
dent antibody responses to influenza virus and have a partial loss of
B cells which accounts for the immunological defects.20
Interestingly, many but not all defects observed in these mice were
also reported for the p52 KO mice,21 therefore supporting the
hypothesis that p52 and BCL-3 form a functional, physiologically
relevant transcriptional complex and induce the expression of many
common target genes. Although BCL-3 is required for the formation
of B cell follicles, it is not clear whether BCL-3 phosphorylation
critically regulates this function. Indeed, chimeric mice that had
been generated by injecting bone marrow precursor cells from
BCL-3 KO mice expressing either wild type or a BCL-3 mutant no
longer phosphorylated by GSK3 did not exhibit any defects in B and
T cells development (unpublished results). However, because of the
decreased transgene expression in the transduced cells, we could not
evaluate the effects of GSK3-mediated BCL-3 phosphorylation over
a long period of time (3–4 months). This issue could be elegantly
elucidated through the generation of knockin mice. As overexpression
of BCL-3 in B cells causes lymphoproliferation and splenomegaly,22
the knockin mice model could allow us to determine the exact role
of BCL-3 in long term, sustained expression.
BCL-3 TARGET GENES
Very few BCL-3 target genes have been identified so far and
include cyclin D1 in breast cancer cells.23 We recently identified
about one hundred genes regulated by BCL-3 in NIH3T3 cells.14
Although the recruitment of this oncoprotein to the corresponding
promoter sequences remains to be experimentally demonstrated, the
expression of some of these BCL-3 target genes such as laminin-β 2
chain (unpublished results) was indeed previously shown to be
altered in Bcl-3 KO mice.24 Moreover, other candidates such as
Cxcl1 were previously described as NF-κB target genes. We are cur-
rently investigating whether the expression levels of BCL-3 and its
target genes can be correlated in lymphomas and breast cancer sam-
ples in order to identify genes that mediate BCL-3 oncogenic poten-
tial in vivo.
LINKING BCL-3 FUNCTIONAL DOMAINS WITH TARGET GENE
EXPRESSION
As a member of the IκB family, BCL-3 harbors ankyrin repeats
that mediate its interaction with p50 or p52. Moreover, these
domains are required for interaction with the HDAC proteins.
Whereas the C-terminal transactivating domain harbors all the
phosphorylated residues identified so far, the N-terminal domain
displays a couple of lysine residues that are critical for BCL-3-medi-
ated transcriptional activation.14 Indeed, a BCL-3 mutant lacking
these residues failed to activate most of the BCL-3 target genes. Why
are these N-terminal lysine residues critical to mediate BCL-3 effects?
Several hypothesis can be made but all of them require experimental
validation. First, these lysine residues are targeted for ubiquitin link-
age and several studies indeed demonstrated that some DNA-bound
transactivation factors are targeted for ubiquitination within their
transactivation domain, this signal being required for transcriptional
activation.25,26 Therefore, there may be a link between BCL-3 ubiq-
uitination and activation. In any case, the molecular mechanism of
BCL-3 ubiquitination and the identity of the ubiquitin E3 ligase
remain unknown. Beside ubiquitination as a mechanism for tran-
scriptional activation, the same lysine residues could also be targeted
for acetylation, a post-translational modification associated with
gene activation.26 We are currently investigating whether BCL-3 is a
substrate of histone acetyltransferases. As a preliminary observation,
some but not all histone acetyltransferases known to acetylate sever-
al transcription factors, enhances BCL-3-mediated transcriptional
activation (our unpublished results). Therefore, BCL-3 may recruit
these proteins in order to activate transcription. However, direct
acetylation of BCL-3 by histone acetyltransferases still needs to be
experimentally demonstrated.
CONCLUSION
Although BCL-3 was identified more than fifteen years ago, most
of its biological roles remains unexplored. The increasing interest for
the role of NF-κB/IκB proteins in cancer will certainly help to better
understand the BCL-3-dependent molecular mechanisms. It is also
likely that phosphorylation will emerge as a critical mechanism for
the regulation of BCL-3 activity.
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